Key points
- GLP-1 medications reduce triglycerides by 15–30% and modestly lower LDL cholesterol
- Tirzepatide shows the strongest lipid-modifying effects among available GLP-1-based treatments
- Improvements are driven by both weight loss and direct metabolic effects on the liver
- GLP-1 medications complement — not replace — statins and other lipid-lowering therapies
- Combined cardiovascular benefits (lipids + blood pressure + inflammation) contribute to the 20% reduction in major cardiac events seen in the SELECT trial
Why cholesterol matters
Cholesterol is a waxy substance carried in the blood by lipoproteins. While essential for cell membranes and hormone production, an unfavourable lipid profile — high LDL cholesterol, high triglycerides, and low HDL cholesterol — is one of the strongest risk factors for atherosclerotic cardiovascular disease, including heart attack and stroke.
In the United Kingdom, approximately 40 per cent of adults have elevated total cholesterol. The relationship between obesity and dyslipidaemia (abnormal blood fats) is well established: excess body fat, particularly visceral fat surrounding the abdominal organs, promotes insulin resistance and drives up triglyceride production in the liver while reducing HDL cholesterol.
This makes the lipid-modifying effects of GLP-1 medications particularly relevant for the millions of UK adults living with both obesity and unfavourable cholesterol profiles.
How GLP-1 medications affect cholesterol
GLP-1 receptor agonists improve the lipid profile through two complementary pathways: indirect effects mediated by weight loss, and direct metabolic effects on the liver and adipose tissue.
Weight-loss-mediated improvements
Losing body weight — particularly visceral fat — reduces hepatic fat content, improves insulin sensitivity and decreases the liver's output of very low-density lipoproteins (VLDL), which carry triglycerides into the bloodstream. For every 5 per cent of body weight lost, triglycerides typically fall by 10–15 per cent, with smaller improvements in LDL and HDL.
Direct hepatic effects
Independent of weight loss, GLP-1 receptor activation appears to directly reduce hepatic lipogenesis (fat production in the liver), improve fatty acid oxidation, and reduce the secretion of triglyceride-rich particles. Research from the STEP and SUSTAIN trial programmes suggests that approximately 30–40 per cent of the lipid improvement seen with semaglutide occurs independently of weight change.
GIP receptor effects (tirzepatide)
Tirzepatide acts on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptor activation has additional effects on adipose tissue metabolism, enhancing fat storage in subcutaneous (rather than visceral) depots and improving adipocyte insulin sensitivity. This dual mechanism likely explains why tirzepatide produces greater lipid improvements than semaglutide alone.
The clinical evidence
Semaglutide trials (STEP programme)
| Lipid marker | Change with semaglutide 2.4 mg | Placebo |
|---|---|---|
| Triglycerides | −18 to −25% | −3 to −5% |
| LDL cholesterol | −3 to −7% | −1 to −2% |
| HDL cholesterol | +2 to +5% | +0 to +1% |
| Total cholesterol | −5 to −8% | −1 to −2% |
| Non-HDL cholesterol | −7 to −10% | −1 to −3% |
Tirzepatide trials (SURMOUNT programme)
| Lipid marker | Change with tirzepatide 15 mg | Placebo |
|---|---|---|
| Triglycerides | −25 to −33% | −4 to −6% |
| LDL cholesterol | −5 to −10% | −1 to −2% |
| HDL cholesterol | +5 to +8% | +1 to +2% |
| Total cholesterol | −6 to −10% | −1 to −3% |
| Non-HDL cholesterol | −10 to −14% | −2 to −3% |
Key takeaway: Tirzepatide produces approximately 30–50 per cent greater triglyceride reduction than semaglutide. This is clinically meaningful, particularly for patients with hypertriglyceridaemia, where elevated triglycerides contribute significantly to cardiovascular risk.
Understanding each lipid marker
Triglycerides
Triglycerides are the fat molecules most directly affected by GLP-1 medications. Elevated triglycerides (above 1.7 mmol/L) are strongly associated with insulin resistance, metabolic syndrome and increased cardiovascular risk. The 15–33 per cent reductions seen with GLP-1 therapies are comparable to those achieved with fibrates, a class of medication specifically designed to lower triglycerides.
For patients who cannot tolerate fibrates or statins, the triglyceride-lowering effect of GLP-1 medications represents a valuable additional benefit alongside weight management.
LDL cholesterol (the “bad” cholesterol)
LDL reductions with GLP-1 medications are modest (3–10 per cent), and considerably less than the 30–50 per cent reductions achieved with moderate-to-high-intensity statin therapy. This is why GLP-1 medications cannot substitute for statins in patients who need significant LDL lowering.
However, GLP-1 medications may improve LDL particle characteristics. Emerging research suggests they shift LDL particles from the small, dense phenotype (which is more atherogenic and harder for the liver to clear) towards larger, more buoyant particles. This qualitative change may reduce cardiovascular risk beyond what the modest numerical LDL reduction would suggest.
HDL cholesterol (the “good” cholesterol)
GLP-1 medications produce small but consistent increases in HDL cholesterol (2–8 per cent). While the absolute change is modest, it reflects improved reverse cholesterol transport — the process by which HDL removes cholesterol from arterial walls and returns it to the liver for excretion.
Non-HDL cholesterol
Non-HDL cholesterol (total cholesterol minus HDL) captures all atherogenic lipoprotein particles, including LDL, VLDL and intermediate-density lipoproteins. It is increasingly used as a treatment target alongside or instead of LDL alone. GLP-1 medications reduce non-HDL cholesterol by 7–14 per cent, reflecting improvements across multiple lipoprotein fractions.
The combined cardiovascular benefit
The lipid improvements from GLP-1 therapy are best understood as part of a broader package of cardiovascular risk reduction. The SELECT trial demonstrated a 20 per cent reduction in major adverse cardiovascular events with semaglutide, and this benefit is likely attributable to the combined effects of:
- Improved lipid profile (triglycerides, LDL, HDL, non-HDL)
- Reduced systemic inflammation (CRP reduction of approximately 38 per cent)
- Lower blood pressure (systolic reduction of 3–6 mmHg)
- Improved glycaemic control (reduced insulin resistance)
- Weight loss (reduced visceral fat burden)
No single mechanism accounts for the cardiovascular protection; it is the synergy of all these metabolic improvements that makes GLP-1 therapy so effective for cardiac risk reduction.
GLP-1 medications and statins: working together
A common question from patients starting GLP-1 therapy is whether they can reduce or stop their statin. The answer is straightforward: GLP-1 medications complement statins, they do not replace them.
Statins remain the gold-standard treatment for elevated LDL cholesterol, with decades of evidence showing they reduce cardiovascular events by 25–35 per cent across a wide range of patient populations. The LDL reduction achieved by statins (30–50 per cent) far exceeds what GLP-1 medications can achieve (3–10 per cent).
However, for patients who remain on a statin and add a GLP-1 medication, the lipid improvements are additive. The statin addresses LDL, while the GLP-1 medication primarily tackles triglycerides and non-HDL cholesterol, providing complementary coverage of the entire atherogenic lipid spectrum.
Important: Never stop or reduce your statin (or any cardiovascular medication) without consulting your doctor, even if your cholesterol numbers have improved on a GLP-1 medication. The cardiovascular protection from statins extends beyond cholesterol reduction alone.
Who benefits most from the lipid effects?
The cholesterol-modifying effects of GLP-1 medications are most clinically significant for patients with:
- Metabolic syndrome: Characterised by elevated triglycerides, low HDL, central obesity, elevated blood pressure and impaired fasting glucose
- Hypertriglyceridaemia: Particularly those with triglycerides above 2.3 mmol/L who remain elevated despite statin therapy
- Non-alcoholic fatty liver disease (NAFLD): Where hepatic lipid accumulation drives dyslipidaemia
- Type 2 diabetes: Where diabetic dyslipidaemia (high triglycerides, low HDL, small dense LDL) is a major contributor to cardiovascular risk
- Statin-intolerant patients: For whom any additional lipid improvement is valuable
Monitoring your lipids on GLP-1 therapy
If you are starting a GLP-1 medication, it is sensible to have a baseline lipid panel (fasting blood test) before treatment and a repeat test at 3–6 months to assess response. Key measurements include total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides and non-HDL cholesterol.
Discuss your results with your GP or prescriber, particularly if you are on a statin or other lipid-lowering medication. Improvements in your lipid profile may support ongoing treatment but should not be grounds for stopping existing cardiovascular therapies without medical advice.